100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET |…
April 27, 2026 17:00 ET | Source: Cabaletta Bio PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq:…
April 27, 2026 17:00 ET | Source: ElevateBio – Posters detail large gene insertion and epigenetic editing capabilities, expanding ElevateBio’s…
April 27, 2026 17:00 ET | Source: Arbor Biotechnologies Inc - Oral presentation highlights novel compact RT editor demonstrating first…